{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:27:58Z","timestamp":1794547678426,"version":"4.9.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008233","name":"Shanghai Jiao Tong University School of Medicine","doi-asserted-by":"publisher","award":["KJ3-0214-24-0011"],"award-info":[{"award-number":["KJ3-0214-24-0011"]}],"id":[{"id":"10.13039\/501100008233","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.eclinm.2025.103464","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T14:30:08Z","timestamp":1756564208000},"page":"103464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7542-5529","authenticated-orcid":false,"given":"Jiaheng","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianren","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4645-1602","authenticated-orcid":false,"given":"Ziyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103464_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2025.103464_bib2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103464_bib3","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103464_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103464_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2022.05.033","article-title":"Cardiovascular disease projections in the United States based on the 2020 census estimates","volume":"80","author":"Mohebi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eclinm.2025.103464_bib6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jama.2018.13022","article-title":"Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US preventive services task force recommendation statement","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103464_bib7","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103464_bib8","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/obr.12889","article-title":"Management of overweight and obesity in primary care-A systematic overview of international evidence-based guidelines","volume":"20","author":"Semlitsch","year":"2019","journal-title":"Obes Rev"},{"key":"10.1016\/j.eclinm.2025.103464_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.mcna.2017.08.006","article-title":"Guideline Recommendations for obesity management","volume":"102","author":"Ryan","year":"2018","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.eclinm.2025.103464_bib10","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2025.103464_bib11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/dom.12251","article-title":"The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems","volume":"16","author":"Seufert","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eclinm.2025.103464_bib12","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3390\/nu13041158","article-title":"Gastric sensory and motor functions and energy intake in health and obesity-therapeutic implications","volume":"13","author":"Cifuentes","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.eclinm.2025.103464_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.eclinm.2025.103464_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2025.103464_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.eclinm.2025.103464_bib16","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2025.103464_bib17","series-title":"Products - health E stats - prevalence of overweight, obesity, and extreme obesity among adults aged 20 and over: United States, 1960\u20131962 through 2017\u20132018","year":"2021"},{"key":"10.1016\/j.eclinm.2025.103464_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.eclinm.2025.103464_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.16005","article-title":"Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: a dose-ranging, phase 2, randomized, placebo-controlled study","volume":"27","author":"Amin","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.eclinm.2025.103464_bib20","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103464_bib21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2025.103464_bib22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2025.103464_bib23","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/dom.15407","article-title":"Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: a multicentre, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"26","author":"Li","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eclinm.2025.103464_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/ejendo\/lvae024","article-title":"Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial","volume":"190","author":"Gatta-Cherifi","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eclinm.2025.103464_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/JCP.0000000000001803","article-title":"Liraglutide in obese or overweight individuals with stable bipolar disorder","volume":"44","author":"McElroy","year":"2024","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.eclinm.2025.103464_bib26","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103464_bib27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/nu15030556","article-title":"Effects of a dulaglutide plus calorie-restricted diet versus a calorie-restricted diet on visceral fat and metabolic profiles in women with polycystic ovary syndrome: a randomized controlled trial","volume":"15","author":"Zhang","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.eclinm.2025.103464_bib28","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41366-023-01370-w","article-title":"A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity","volume":"47","author":"Coppin","year":"2023","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.eclinm.2025.103464_bib29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103464_bib30","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamasurg.2023.2930","article-title":"Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial","volume":"158","author":"Mok","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.eclinm.2025.103464_bib31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103464_bib32","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103464_bib33","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2025.103464_bib34","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/oby.23395","article-title":"Exenatide for weight-loss maintenance in adolescents with severe obesity: a randomized, placebo-controlled trial","volume":"30","author":"Fox","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.eclinm.2025.103464_bib35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103464_bib36","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103464_bib37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103464_bib38","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103464_bib39","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2025.103464_bib40","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103464_bib41","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.23098","article-title":"Liraglutide does not adversely impact fat-free mass loss","volume":"29","author":"Grannell","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.eclinm.2025.103464_bib42","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103464_bib43","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103464_bib44","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/oby.22653","article-title":"Effects of liraglutide and behavioral weight loss on food cravings, eating behaviors, and eating disorder psychopathology","volume":"27","author":"Chao","year":"2019","journal-title":"Obesity"},{"key":"10.1016\/j.eclinm.2025.103464_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12933-019-0945-7","volume":"18","author":"Peradze","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.eclinm.2025.103464_bib46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103464_bib47","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103464_bib48","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes"},{"key":"10.1016\/j.eclinm.2025.103464_bib49","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/ijo.2014.177","article-title":"Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss","volume":"39","author":"Iepsen","year":"2015","journal-title":"Int J Obes"},{"key":"10.1016\/j.eclinm.2025.103464_bib50","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eclinm.2025.103464_bib51","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103464_bib52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1037\/amp0000517","article-title":"Lifestyle modification approaches for the treatment of obesity in adults","volume":"75","author":"Wadden","year":"2020","journal-title":"Am Psychol"},{"key":"10.1016\/j.eclinm.2025.103464_bib53","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"Sumithran","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103464_bib54","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.eclinm.2025.103464_bib55","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s42255-024-01168-8","article-title":"Molecular connectomics reveals a glucagon-like peptide 1-sensitive neural circuit for satiety","volume":"6","author":"Webster","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.eclinm.2025.103464_bib56","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/00325481.2015.1090295","article-title":"User's guide to mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","author":"Shaefer","year":"2015","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.eclinm.2025.103464_bib57","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes Rev"},{"key":"10.1016\/j.eclinm.2025.103464_bib58","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/imj.16126","article-title":"Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review","volume":"53","author":"Stretton","year":"2023","journal-title":"Intern Med J"},{"key":"10.1016\/j.eclinm.2025.103464_bib59","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1210\/clinem\/dgae176","article-title":"Effect of glucagon-like peptide-1 receptor agonists (GLP-1RA) on weight loss following bariatric treatment","volume":"109","author":"Kramer","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eclinm.2025.103464_bib60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis","volume":"30","author":"Ansari","year":"2024","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eclinm.2025.103464_bib61","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.eclinm.2025.103464_bib62","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241281903","article-title":"Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP\/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis","volume":"17","author":"Stefanou","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.eclinm.2025.103464_bib63","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/23969873241234238","article-title":"Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP\/GLP-1 receptor agonist tirzepatide for type 2 diabetes: a systematic review and meta-analysis","volume":"9","author":"Stefanou","year":"2024","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.eclinm.2025.103464_bib64","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eclinm.2025.103464_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:10:21Z","timestamp":1794546621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025003967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":65,"alternative-id":["S2589537025003967"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103464","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of lifestyle modification combined with GLP-1 receptor agonists on body weight and cardiometabolic biomarkers in individuals with overweight or obesity: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103464"}}